Lipid profile changes after switch to atazanavir from other protease inhibitor-based combined antiretroviral treatment in hiv-infected korean

Ji Hyeon Baek, Young Goo Song, Chang Oh Kim, Su Jin Jeong, Nam Soo Koo, Hye Won Kim, Sang Hoon Han, JunYong Choi, June Myung Kim

Research output: Contribution to journalComment/debate

Abstract

Dyslipidemia, one of the major disadvantages of use of protease inhibitor (PI), is a risk factor for cardiovascular disease in HIV-infected patients receiving antiretroviral treatment. Little is known about the effect of a switch from another PI to unboosted atazanavir (ATV) on the lipid profile. The aim of this study was to evaluate changes in the lipid profile after switching from another PI to either unboosted or boosted ATV in HIV-infected Koreans. We retrospectively collected data on the serum lipid profile at the time of the switch (week 0), and weeks 12 and 24 after the switch, as well as clinical characteristics at week 0 in a total of 27 patients. Triglyceride (TG) showed a significant decrease at weeks 12 and 24 in all patients (196 vs. 174 mg/dL, P=0.048 and 196 vs. 150 mg/dL, P=0.021, respectively). However, these effects were only observed in the unboosted ATV group (N=14; 239 vs. 125 mg/dL, P=0.017 and 239 vs. 87 mg/dL, P=0.021, respectively). For total cholesterol, only the unboosted ATV group at 24 weeks showed a significant decrease (184 vs. 158 mg/dL, P=0.031). No significant changes were observed in LDL- and HDL-cholesterol at weeks 12 and 24 in both the unboosted and boosted ATV groups. These results suggest that changing to unboosted ATV from another PI may ameliorate high TG and total cholesterol in HIV-infected Koreans.

Original languageEnglish
Pages (from-to)377-381
Number of pages5
JournalInfection and Chemotherapy
Volume44
Issue number5
DOIs
Publication statusPublished - 2012 Dec 1

Fingerprint

Protease Inhibitors
Lipids
HIV
Triglycerides
Therapeutics
Cholesterol
Dyslipidemias
LDL Cholesterol
HDL Cholesterol
Atazanavir Sulfate
Cardiovascular Diseases
Serum

All Science Journal Classification (ASJC) codes

  • Infectious Diseases
  • Pharmacology (medical)

Cite this

Baek, Ji Hyeon ; Song, Young Goo ; Kim, Chang Oh ; Jeong, Su Jin ; Koo, Nam Soo ; Kim, Hye Won ; Han, Sang Hoon ; Choi, JunYong ; Kim, June Myung. / Lipid profile changes after switch to atazanavir from other protease inhibitor-based combined antiretroviral treatment in hiv-infected korean. In: Infection and Chemotherapy. 2012 ; Vol. 44, No. 5. pp. 377-381.
@article{63bf3d126f8d4ccb92f2cb8346cec2e6,
title = "Lipid profile changes after switch to atazanavir from other protease inhibitor-based combined antiretroviral treatment in hiv-infected korean",
abstract = "Dyslipidemia, one of the major disadvantages of use of protease inhibitor (PI), is a risk factor for cardiovascular disease in HIV-infected patients receiving antiretroviral treatment. Little is known about the effect of a switch from another PI to unboosted atazanavir (ATV) on the lipid profile. The aim of this study was to evaluate changes in the lipid profile after switching from another PI to either unboosted or boosted ATV in HIV-infected Koreans. We retrospectively collected data on the serum lipid profile at the time of the switch (week 0), and weeks 12 and 24 after the switch, as well as clinical characteristics at week 0 in a total of 27 patients. Triglyceride (TG) showed a significant decrease at weeks 12 and 24 in all patients (196 vs. 174 mg/dL, P=0.048 and 196 vs. 150 mg/dL, P=0.021, respectively). However, these effects were only observed in the unboosted ATV group (N=14; 239 vs. 125 mg/dL, P=0.017 and 239 vs. 87 mg/dL, P=0.021, respectively). For total cholesterol, only the unboosted ATV group at 24 weeks showed a significant decrease (184 vs. 158 mg/dL, P=0.031). No significant changes were observed in LDL- and HDL-cholesterol at weeks 12 and 24 in both the unboosted and boosted ATV groups. These results suggest that changing to unboosted ATV from another PI may ameliorate high TG and total cholesterol in HIV-infected Koreans.",
author = "Baek, {Ji Hyeon} and Song, {Young Goo} and Kim, {Chang Oh} and Jeong, {Su Jin} and Koo, {Nam Soo} and Kim, {Hye Won} and Han, {Sang Hoon} and JunYong Choi and Kim, {June Myung}",
year = "2012",
month = "12",
day = "1",
doi = "10.3947/ic.2012.44.5.377",
language = "English",
volume = "44",
pages = "377--381",
journal = "Infection and Chemotherapy",
issn = "2093-2340",
publisher = "Taehan Kamyom Hakhoe, Taehan Hwahak Yopop Hakhoe",
number = "5",

}

Lipid profile changes after switch to atazanavir from other protease inhibitor-based combined antiretroviral treatment in hiv-infected korean. / Baek, Ji Hyeon; Song, Young Goo; Kim, Chang Oh; Jeong, Su Jin; Koo, Nam Soo; Kim, Hye Won; Han, Sang Hoon; Choi, JunYong; Kim, June Myung.

In: Infection and Chemotherapy, Vol. 44, No. 5, 01.12.2012, p. 377-381.

Research output: Contribution to journalComment/debate

TY - JOUR

T1 - Lipid profile changes after switch to atazanavir from other protease inhibitor-based combined antiretroviral treatment in hiv-infected korean

AU - Baek, Ji Hyeon

AU - Song, Young Goo

AU - Kim, Chang Oh

AU - Jeong, Su Jin

AU - Koo, Nam Soo

AU - Kim, Hye Won

AU - Han, Sang Hoon

AU - Choi, JunYong

AU - Kim, June Myung

PY - 2012/12/1

Y1 - 2012/12/1

N2 - Dyslipidemia, one of the major disadvantages of use of protease inhibitor (PI), is a risk factor for cardiovascular disease in HIV-infected patients receiving antiretroviral treatment. Little is known about the effect of a switch from another PI to unboosted atazanavir (ATV) on the lipid profile. The aim of this study was to evaluate changes in the lipid profile after switching from another PI to either unboosted or boosted ATV in HIV-infected Koreans. We retrospectively collected data on the serum lipid profile at the time of the switch (week 0), and weeks 12 and 24 after the switch, as well as clinical characteristics at week 0 in a total of 27 patients. Triglyceride (TG) showed a significant decrease at weeks 12 and 24 in all patients (196 vs. 174 mg/dL, P=0.048 and 196 vs. 150 mg/dL, P=0.021, respectively). However, these effects were only observed in the unboosted ATV group (N=14; 239 vs. 125 mg/dL, P=0.017 and 239 vs. 87 mg/dL, P=0.021, respectively). For total cholesterol, only the unboosted ATV group at 24 weeks showed a significant decrease (184 vs. 158 mg/dL, P=0.031). No significant changes were observed in LDL- and HDL-cholesterol at weeks 12 and 24 in both the unboosted and boosted ATV groups. These results suggest that changing to unboosted ATV from another PI may ameliorate high TG and total cholesterol in HIV-infected Koreans.

AB - Dyslipidemia, one of the major disadvantages of use of protease inhibitor (PI), is a risk factor for cardiovascular disease in HIV-infected patients receiving antiretroviral treatment. Little is known about the effect of a switch from another PI to unboosted atazanavir (ATV) on the lipid profile. The aim of this study was to evaluate changes in the lipid profile after switching from another PI to either unboosted or boosted ATV in HIV-infected Koreans. We retrospectively collected data on the serum lipid profile at the time of the switch (week 0), and weeks 12 and 24 after the switch, as well as clinical characteristics at week 0 in a total of 27 patients. Triglyceride (TG) showed a significant decrease at weeks 12 and 24 in all patients (196 vs. 174 mg/dL, P=0.048 and 196 vs. 150 mg/dL, P=0.021, respectively). However, these effects were only observed in the unboosted ATV group (N=14; 239 vs. 125 mg/dL, P=0.017 and 239 vs. 87 mg/dL, P=0.021, respectively). For total cholesterol, only the unboosted ATV group at 24 weeks showed a significant decrease (184 vs. 158 mg/dL, P=0.031). No significant changes were observed in LDL- and HDL-cholesterol at weeks 12 and 24 in both the unboosted and boosted ATV groups. These results suggest that changing to unboosted ATV from another PI may ameliorate high TG and total cholesterol in HIV-infected Koreans.

UR - http://www.scopus.com/inward/record.url?scp=84872845218&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84872845218&partnerID=8YFLogxK

U2 - 10.3947/ic.2012.44.5.377

DO - 10.3947/ic.2012.44.5.377

M3 - Comment/debate

VL - 44

SP - 377

EP - 381

JO - Infection and Chemotherapy

JF - Infection and Chemotherapy

SN - 2093-2340

IS - 5

ER -